We then sought to examine whether Lapatinib and Broussoflavonol B are still able to disrupt the ER-α36-EGFR/HER2 regulatory loops in ER-positive breast cancer stem/progenitor cells. This evidence concerns the gene EGFR and breast carcinoma.